T Peel1, D May2, K Buising3, K Thursky4, M Slavin4, P Choong5. 1. Department of Surgery, St Vincent's Hospital, University of Melbourne, Regent Street, Fitzroy, VIC 3065, Australia; Department of Infectious Diseases, St Vincent's Hospital Melbourne, Victoria Parade, Fitzroy, VIC 3065, Australia; Department of Orthopaedics, St Vincent's Hospital Melbourne, Victoria Parade, Fitzroy, VIC 3065, Australia. Electronic address: tnpeel@student.unimelb.edu.au. 2. Department of Orthopaedics, St Vincent's Hospital Melbourne, Victoria Parade, Fitzroy, VIC 3065, Australia. 3. Department of Infectious Diseases, St Vincent's Hospital Melbourne, Victoria Parade, Fitzroy, VIC 3065, Australia. 4. Department of Infectious Diseases, Peter MacCallum Cancer Centre, Lansdowne St, East Melbourne, VIC 3002, Australia. 5. Department of Surgery, St Vincent's Hospital, University of Melbourne, Regent Street, Fitzroy, VIC 3065, Australia; Department of Orthopaedics, St Vincent's Hospital Melbourne, Victoria Parade, Fitzroy, VIC 3065, Australia.
Abstract
AIMS: This study aims to describe the incidence of infective complications, including tumour endoprosthesis infection, in a cohort of patients undergoing tumour endoprosthesis surgery in Victoria, Australia. METHODS: This retrospective cohort study was performed over 15 years (January 1996-December 2010). RESULTS: 121 patients underwent tumour endoprosthesis surgery during the study period. Patients were followed for a median of 34 months (interquartile range [IQR] 17, 80). Overall, 34 patients (28%) experienced infective complications including: bacteraemia in 19 patients (16%) and tumour endoprosthesis infection in 17 (14%). The majority of patients with early and late acute infections (haematogenous) were managed with debridement and retention of the prosthesis in addition to biofilm-active antibiotics. Late chronic infections were predominantly managed by exchange of the prosthesis. The overall success rate of treatment was 71%. The success rate for debridement and retention was 75% compared with 67% for exchange procedures. CONCLUSIONS: There is a significant rate of infective complications following tumour endoprosthesis surgery including 14% of patients experiencing infection involving the tumour endoprosthesis. This study is the first to report on outcomes from debridement and retention of the prosthesis; which had comparable success rates to other treatment modalities. Crown
AIMS: This study aims to describe the incidence of infective complications, including tumour endoprosthesis infection, in a cohort of patients undergoing tumour endoprosthesis surgery in Victoria, Australia. METHODS: This retrospective cohort study was performed over 15 years (January 1996-December 2010). RESULTS: 121 patients underwent tumour endoprosthesis surgery during the study period. Patients were followed for a median of 34 months (interquartile range [IQR] 17, 80). Overall, 34 patients (28%) experienced infective complications including: bacteraemia in 19patients (16%) and tumour endoprosthesis infection in 17 (14%). The majority of patients with early and late acute infections (haematogenous) were managed with debridement and retention of the prosthesis in addition to biofilm-active antibiotics. Late chronic infections were predominantly managed by exchange of the prosthesis. The overall success rate of treatment was 71%. The success rate for debridement and retention was 75% compared with 67% for exchange procedures. CONCLUSIONS: There is a significant rate of infective complications following tumour endoprosthesis surgery including 14% of patients experiencing infection involving the tumour endoprosthesis. This study is the first to report on outcomes from debridement and retention of the prosthesis; which had comparable success rates to other treatment modalities. Crown
Authors: C Theil; J Röder; G Gosheger; N Deventer; R Dieckmann; D Schorn; J Hardes; D Andreou Journal: Clin Orthop Relat Res Date: 2019-12 Impact factor: 4.176
Authors: Isabelle S Byers; Nicholas A Turner; Nicole L Levine; Alexander L Lazarides; Daniel R Evans; Ivan Spasojevic; Ping Fan; Sin-Ho Jung; Junheng Gao; Julia D Visgauss; Brian E Brigman; William C Eward Journal: Antimicrob Agents Chemother Date: 2022-09-27 Impact factor: 5.938